Portal Vein Thrombosis in Liver Transplantation: A Retrospective Cohort Study.

Autor: Barrera-Lozano LM; Transplant Department, Hospital San Vicente Fundación, Rionegro 054047, Colombia.; Vascular Medicine Department, Faculty of Medicine, Universidad de Antioquia UdeA, Medellín 050010, Colombia., Ramírez-Arbeláez JA; Transplant Department, Hospital San Vicente Fundación, Rionegro 054047, Colombia., Muñoz CL; Transplant Department, Hospital San Vicente Fundación, Rionegro 054047, Colombia., Becerra JA; Foscal Clinic, Floridablanca 681003, Colombia., Toro LG; Transplant Department, Hospital San Vicente Fundación, Rionegro 054047, Colombia., Ardila CM; Basic Studies Department, School of Dentistry, Universidad de Antioquia UdeA, Medellín 050010, Colombia.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2023 Jun 09; Vol. 12 (12). Date of Electronic Publication: 2023 Jun 09.
DOI: 10.3390/jcm12123951
Abstrakt: Portal vein thrombosis was considered a contraindication for liver transplantation. This study analyzes the perioperative complications and survival of liver transplant patients with portal vein thrombosis (PVT). A retrospective observational cohort study of liver transplant patients was conducted. The outcomes were early mortality (30 days) and patient survival. A total of 201 liver transplant patients were identified and 34 (17%) patients with PVT were found. The most frequent extension of thrombosis was Yerdel 1 (58.8%), and a portosystemic shunt was identified in 23 (68%) patients. Eleven patients (33%) presented any early vascular complication, PVT being the most frequent (12%). The multivariate regression analysis showed a statistically significant association between PVT and early complications (OR = 3.3, 95% confidence interval 1.4-7.7; p = 0.006). Moreover, early mortality was observed in eight patients (24%), of which two (5.9%) presented Yerdel 2. For Yerdel 1, patient survival according to the extent of thrombosis was 75% at 1 year and 3 years, while for Yerdel 2, it was 65% at 1 year, and 50% at 3 years ( p = 0.04). Portal vein thrombosis significantly influenced early vascular complications. Furthermore, portal vein thrombosis Yerdel 2 or higher impacts the survival of liver grafts in the short and long term.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje